Company news

Moleculin Biotech, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Moleculin Announces Positive Interim Results in Pediatric Brain Tumor Phase 1 Clinical Trial at Emory University

September 30, 2020

Moleculin Announces Discovery of Significant In Vitro Activity Against COVID-19 Virus for New Antimetabolites

September 28, 2020

Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122

September 13, 2020

Moleculin Announces Successful Completion of Pre-IND Meeting with the FDA

September 8, 2020

Moleculin Biotech, Inc. Reports Financial Results for the Quarter Ended June 30, 2020

August 11, 2020

Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate

July 14, 2020

Moleculin Provides Update on Annamycin Clinical Development

July 1, 2020

Moleculin Announces Preclinical Data Confirms Efficacy of Annamycin in Lung Metastases

June 24, 2020

Moleculin Announces Confirmatory In Vitro Analysis of WP1122

June 15, 2020

Moleculin Announces Submission to Expand Clinical Sites in European AML Trial

June 3, 2020

Moleculin Announces Emory University Clinical Trial of WP1066 Begins Enrollment

June 1, 2020

Moleculin Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

May 26, 2020

Moleculin Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 15, 2020

May 7, 2020

Moleculin Approved to Accelerate European Clinical Trial

April 27, 2020

Moleculin Announces Head of NIAID Antiviral Drug Discovery and Development Center Joins COVID-19 Drug Development Team

April 21, 2020

Moleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus Testing

April 19, 2020

Moleculin Announces Leading Virologist Joins Development Team

April 14, 2020

Moleculin Announces Active Compound in WP1122 Reduces Coronavirus Replication In Vitro by 100%

April 7, 2020

Moleculin Announces Additional Positive Safety Data in EU AML Trial

April 1, 2020

Moleculin Announces Patent Filing to Cover New Coronavirus Drug Candidate

March 19, 2020

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2019

March 18, 2020

Moleculin Signs Agreement with UTMB to Test WP1122 on a Range of Viruses, Including Coronavirus

March 16, 2020

Moleculin Announces Dr. Hongbo Zhai Joins Science Advisory Board

March 9, 2020

Moleculin Announces Positive Independent Report of No Cardiotoxicity in Annamycin Phase 1 To Date

February 19, 2020

Moleculin Announces $6.0 Million Registered Direct Offering

February 5, 2020

Moleculin to Seek Accelerated FDA Approval and Plans for Pivotal Phase 2 AML Trial

February 4, 2020

Moleculin Announces Successful Completion of US Phase 1 AML Trial of Annamycin

February 2, 2020

Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

December 3, 2019

Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients

November 18, 2019

Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

November 12, 2019

Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial

November 11, 2019

Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models

October 28, 2019

Moleculin Increases Annamycin Production Due to Positive Clinical Trial Activity and Expanded Potential Indications

October 21, 2019

Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery

September 15, 2019

Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019

August 15, 2019

Moleculin Announces Completion of Lymphoma Trial Enrollment

August 12, 2019

Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models

August 5, 2019

Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort

July 17, 2019

Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation

July 9, 2019

Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019

May 13, 2019

Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019

April 21, 2019

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin

April 17, 2019

Moleculin Announces Significant Discovery in Lung Cancer Models

April 16, 2019

Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial

April 10, 2019

Moleculin Announces Successful Expansion of its Leukemia Drug Program

April 8, 2019

Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting

April 2, 2019

← Newer news releases

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 53 decks. Every deck is listed under its year.